IQVIA has announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies.

This solutions suite, supported by more than 1,000 dedicated employees, will deliver simplified operating procedures, specialized teams, and services to provide a more agile way for these innovators to reach their drug development and commercialization milestones. From initial planning to trial design and implementation to market launch and commercialization, IQVIA Biotech delivers a transparent and streamlined process with a deep foundation in science.

IQVIA’s novel solutions incorporate unparalleled real world evidence resources, advanced analytics, and transformative technology to drive efficiencies and innovation. The company’s deep therapeutic and scientific expertise allows the IQVIA Biotech team to address specific needs at each milestone on the clinical development path and on the pre- and post-approval commercialization path.

Key therapy areas for IQVIA Biotech include oncology, central nervous system, dermatology, cardiovascular, and immunology, among many areas of expertise. But at the core of this offering is the team serving these clients.